Home » Stocks » PRQR

ProQR Therapeutics N.V. (PRQR)

Stock Price: $4.57 USD 0.02 (0.44%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $4.56 -0.01 (-0.22%) Feb 26, 5:00 PM
Market Cap 229.17M
Revenue (ttm) 2.17M
Net Income (ttm) -63.76M
Shares Out 41.04M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $4.57
Previous Close $4.55
Change ($) 0.02
Change (%) 0.44%
Day's Open 4.48
Day's Range 4.26 - 4.64
Day's Volume 541,717
52-Week Range 3.40 - 8.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of ...

GlobeNewsWire - 1 week ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of ...

GlobeNewsWire - 1 month ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

GlobeNewsWire - 2 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of ...

GlobeNewsWire - 3 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of ...

Zacks Investment Research - 3 months ago

ProQR (PRQR) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of ...

GlobeNewsWire - 3 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RN...

GlobeNewsWire - 4 months ago

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally

GlobeNewsWire - 5 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...

GlobeNewsWire - 5 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation ...

Seeking Alpha - 5 months ago

ProQR Therapeutics: Bringing A New Cure To The Market

GlobeNewsWire - 6 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation o...

GlobeNewsWire - 7 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative ...

GlobeNewsWire - 7 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformati...

GlobeNewsWire - 7 months ago

Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data Call on July 20 will include a snapsh...

Zacks Investment Research - 8 months ago

At this stage, we have narrowed down our search to five low-beta stocks that have provided double-digit returns in the past month.

Other stocks mentioned: OOMA, SPWH, SWBI, ZS
Zacks Investment Research - 8 months ago

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: ATXI, BJ, FRO, ICLK
GlobeNewsWire - 8 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative ...

Zacks Investment Research - 8 months ago

ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

Leiden, Netherlands & Cambridge, Mass., May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...

Zacks Investment Research - 9 months ago

ProQR (PRQR) delivered earnings and revenue surprises of 23.91% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) --  March 31, 2020 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives th...

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation o...

GlobeNewsWire - 1 year ago

My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S. My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.

GlobeNewsWire - 1 year ago

Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene Designation is for the treatment of patients with retinitis pigmentosa c...

Zacks Investment Research - 1 year ago

ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformativ...

24/7 Wall Street - 1 year ago

ProQR Therapeutics N.V. (NASDAQ: PRQR) shares jumped early on Thursday after the firm announced that it received Orphan Drug designation (ODD) from the U.S.

Market Watch - 1 year ago

Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123.

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformativ...

Zacks Investment Research - 1 year ago

ProQR (PRQR) delivered earnings and revenue surprises of -9.38% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor ProQR Therapeutics.

GlobeNewsWire - 1 year ago

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transfor...

GlobeNewsWire - 1 year ago

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the cr...

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creatio...

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative ...

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformativ...

GlobeNewsWire - 1 year ago

LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformat...

Zacks Investment Research - 1 year ago

ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformati...

Seeking Alpha - 1 year ago

Today, we look at a small developmental biotech concern from across the pond named ProQR Therapeutics.

GlobeNewsWire - 1 year ago

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformati...

Zacks Investment Research - 1 year ago

ProQR (PRQR) delivered earnings and revenue surprises of 24.44% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Shares have lost half of their value since my initial article.

Zacks Investment Research - 1 year ago

ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

About PRQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical t... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2014
CEO
Daniel De Boer
Stock Exchange
NASDAQ
Ticker Symbol
PRQR
Full Company Profile

Financial Performance

In 2019, PRQR's revenue was 1.93 million, a decrease of -66.45% compared to the previous year's 5.76 million. Losses were -56.75 million, 53.0% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 366.74% from the latest price.

Price Target
$21.33
(366.74% upside)
Analyst Consensus: Strong Buy